Erlend Petter Skagseth

Sarsia Seed Management AS is a venture capital firm headquartered in Bergen, Norway. The company was founded in 2006.

Blue Limit AS is a holding company that develops, protects, produces, and sells early stage larvae feed for shrimp and mollusks. The firm offers feed for the vulnerable early development phases of fish and shellfish larvae. It is a norwegian aquaculture feed company that launches shrimp larvae feed. The firm is categorized under other research and experimental development on natural sciences and engineering. The company was founded by Anders Aksnes on June 29, 2006 and is headquartered in Bergen, Norway.

Delante Health AS specializes in the manufacture of nutritional products. It engages in the production of products with vitamins and minerals. The firm's product platform Lipidfizz is a patented omega-3 drink powder delivered in individual servings. Its technology enables consumption of omega-3 and other polyunsaturated fatty acids in effervescent powders and tablets. The company was founded by Hans Robert Wahren and Bjørn Skjævestad in 2005 and is headquartered in Bekkestua, Norway.

GeneSeque AS provides single-molecule DNA-sequencing technology. It develops MagSeq, a break-through technology for single-molecule sequencing. The company was founded on February 12, 2008 and is headquartered in Trondheim, Norway.

Seafarm Solutions AS designs, produces, and sells goods and services to the fishing industry. It manufactures machines and equipment for the fish farmers. The company was founded by Claus Mikael Søberg and Morten Aga on August 10, 2000 and is headquartered in Vaksdal, Norway.

Caerus Capital AS develops a process to produce heparin from marine raw materials. It focuses on developing novel anticoagulant agents based on biomass from the fish farming industry. The firm's technological platform is based on patented processes for extraction and purification of heparin using marine species-specifically salmon intestines-as raw material. The company was founded by Ragnar Flengsrud on December 4, 2001 and is headquartered in Hovik, Norway.

APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway.